PDF(Pubmed)
Abstract：
Understanding the molecular mechanisms underlying neuro-urological disorders is crucial for the development of targeted therapeutic interventions. Through the establishment of comprehensive biobanks, researchers can collect and store various biological specimens, including urine, blood, tissue, and DNA samples, to study these mechanisms. In the context of neuro-urology, biobanking facilitates the identification of genetic variations, epigenetic modifications, and gene expression patterns associated with neurogenic lower urinary tract dysfunction. These conditions often present as symptoms of neurological diseases such as Alzheimer\'s disease, multiple sclerosis, Parkinson\'s disease, spinal cord injury, and many others. Biobanking of tissue specimens from such patients is essential to understand why these diseases cause the respective symptoms and what can be done to alleviate them. The utilization of high-throughput technologies, such as next-generation sequencing and gene expression profiling, enables researchers to explore the molecular landscape of these conditions in an unprecedented manner. The development of specific and reliable biomarkers resulting from these efforts may help in early detection, accurate diagnosis, and effective monitoring of neuro-urological conditions, leading to improved patient care and management. Furthermore, these biomarkers could potentially facilitate the monitoring of novel therapies currently under investigation in neuro-urological clinical trials. This comprehensive review explores the synergistic integration of neuro-urology and biobanking, with particular emphasis on the translation of biobanking approaches in molecular research in neuro-urology. We discuss the advantages of biobanking in neuro-urological studies, the types of specimens collected and their applications in translational research. Furthermore, we highlight the importance of standardization and quality assurance when collecting samples and discuss challenges that may compromise sample quality and impose limitations on their subsequent utilization. Finally, we give recommendations for sampling in multicenter studies, examine sustainability issues associated with biobanking, and provide future directions for this dynamic field.
摘要：
了解神经泌尿系统疾病的分子机制对于发展有针对性的治疗干预措施至关重要。通过建立综合性生物银行，研究人员可以收集和储存各种生物标本，包括尿液,血,组织,和DNA样本,研究这些机制。在神经泌尿学方面,生物带有利于遗传变异的识别，表观遗传修饰,和与神经源性下尿路功能障碍相关的基因表达模式。这些情况通常表现为神经疾病的症状，如阿尔茨海默病，多发性硬化症,帕金森病,脊髓损伤,和许多其他人。对这些患者的组织样本进行生物分析对于理解为什么这些疾病会导致各自的症状以及可以采取什么措施来缓解这些症状至关重要。利用高通量技术，如下一代测序和基因表达谱分析，使研究人员能够以前所未有的方式探索这些条件的分子景观。这些努力导致的特定和可靠的生物标志物的开发可能有助于早期检测，准确诊断,以及对神经泌尿系统状况的有效监测，改善患者护理和管理。此外，这些生物标志物可能有助于监测神经泌尿学临床试验中目前正在研究的新疗法.这篇全面的综述探讨了神经泌尿学和生物样本的协同整合，特别强调神经泌尿学分子研究中生物库方法的翻译。我们讨论了神经泌尿学研究中生物库的优势，采集的标本类型及其在转化研究中的应用。此外，我们强调了在收集样品时标准化和质量保证的重要性，并讨论了可能损害样品质量并限制其后续使用的挑战。最后,我们为多中心研究中的抽样提供建议，检查与生物作业相关的可持续性问题，并为这个动态领域提供未来的方向。
